ONC Stock Analysis: Buy, Sell, or Hold?
ONC - BeOne Medicines Ltd. American Depositary Shares
$347.48
-8.53 (-2.40%)
▼
5d:
-0.23%
30d:
+9.47%
90d:
+14.07%
WAIT
LOW Confidence
Analysis Updated: Aug 14, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When ONC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ONC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ONC shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$500.66
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$310.87
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ONC is currently trading at $347.48, which is considered extended relative to its 30-day fair value range of $304.29 to $332.57. The stock's valuation (Forward PE: 33.8) is in line with its historical norms (37.3). Remarkably, the market is currently pricing in an annual earnings decline of 3.3% over the next few years. This pessimistic expectation contrasts with the company's recent 166.7% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ONC is in a uptrend. Immediate support is located at $309.94, while resistance sits at $366.99.
Market Sentiment: ONC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $433.02 (+24.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ONC is in a uptrend. Immediate support is located at $309.94, while resistance sits at $366.99.
Market Sentiment: ONC scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $433.02 (+24.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$304.29 -
$332.57
Company Quality Score
33/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
28.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 24.6% below Wall St target ($433.02)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$304.29 -
$332.57
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$309.94
Resistance Level
$366.99
Current Trend
Uptrend
Technical data as of
Aug 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
33.79
Wall Street Target
$433.02
(+24.6%)
Revenue Growth (YoY)
29.6%
Earnings Growth (YoY)
166.7%
Profit Margin
10.7%
Valuation Discount vs History
-3.3% cheaper
PE vs Historical
33.8 vs 37.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.3%
(market-implied from PE analysis)
1-Year Target
$336.01
(-3%)
2-Year Target
$324.92
(-7%)
3-Year Target
$314.20
(-10%)
3-Yr Target (if PE normalizes)
(PE: 34→37)
$346.85
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 33.8, Growth: 35.4%)
$861.74
(+148%)
Base:
(SPY PE: 20.2, Growth: 35.4%)
$515.94
(+49%)
Bear:
(PE: 17.2, Growth: 35.4%)
$438.55
(+26%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (47x PE), but valuation improves significantly next year (34x PE) as earnings recover.
Forward PE: 46.51 | Forward EPS (Implied): $7.47
Bull Case
$419.58
(+21%)
Analyst growth 15.0%, PE expands to 48.8
Base Case
$347.48
(0%)
Market implied 0.0%, PE stable at 46.5
Bear Case
$265.82
(-24%)
Severe decline -15.0%, PE contracts to 41.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 33.8 to 37.3
Stabilization Target:
$383.59
(+10.4%)
PE Expansion Potential:
+10.4%
Share & Embed Analysis
Last updated: August 16, 2026 1:44 AM ET
Data refreshes hourly during market hours. Next update: 2:44 AM
Data refreshes hourly during market hours. Next update: 2:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ONC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
2
Sells
Net
INSIDERS SELLING
Recent Transactions
Chan Henry Lee
SELL
332 shares
2026-04-08
Chan Henry Lee
SELL
341 shares
2026-03-11
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 41 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 49 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 43 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$140 | 67 BUY |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
13 analysts |
$19 | 55 HOLD |